William Blair Starts LogicBio Therapeutics (LOGC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chardan Capital Markets Starts LogicBio Therapeutics (LOGC) at Buy
November 13, 2018 6:47 AM ESTChardan Capital Markets analyst Gbola Amusa initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Buy rating and a price target of $20.00.
The analyst comments "LogicBios pipeline reflects a focus on indications that play to its strengths. The advantage lies in indications where 1)... More
Barclays Starts LogicBio Therapeutics (LOGC) at Overweight
November 13, 2018 4:16 AM ESTBarclays analyst Gena Wang initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Overweight rating and a price target of $24.00.
For an analyst ratings summary and ratings history on LogicBio Therapeutics click here. For more ratings news on LogicBio Therapeutics click here.
Shares of LogicBio Therapeutics closed at $13.72 yesterday.
... More